92 related articles for article (PubMed ID: 35417017)
1. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
O'Brien NA; Huang HKT; McDermott MSJ; Madrid AM; Luo T; Ayala R; Issakhanian S; Gong KW; Lu M; Zhang J; Slamon DJ
Mol Cancer Ther; 2022 May; 21(5):751-761. PubMed ID: 35417017
[TBL] [Abstract][Full Text] [Related]
2. Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer.
Rodriguez GF; Shah A; Maderal AD
Breast Dis; 2024; 43(1):61-64. PubMed ID: 38578876
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
Casak SJ; Horiba MN; Yuan M; Cheng J; Lemery SJ; Shen YL; Fu W; Moore JN; Li Y; Bi Y; Auth D; Fesenko N; Kluetz PG; Pazdur R; Fashoyin-Aje LA
Clin Cancer Res; 2023 Nov; 29(21):4326-4330. PubMed ID: 37318379
[TBL] [Abstract][Full Text] [Related]
4. Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients.
Tosca EM; Borella E; Piana C; Bouchene S; Merlino G; Fiascarelli A; Mazzei P; Magni P
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1626-1639. PubMed ID: 36793223
[TBL] [Abstract][Full Text] [Related]
5. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients.
Lux MP; Schneeweiss A; Hartkopf AD; Müller V; Janni W; Belleville E; Stickeler E; Thill M; Fasching PA; Kolberg HC; Untch M; Harbeck N; Wöckel A; Thomssen C; Schulmeyer CE; Welslau M; Overkamp F; Schütz F; Lüftner D; Ditsch N
Geburtshilfe Frauenheilkd; 2021 Apr; 81(4):469-480. PubMed ID: 33867564
[TBL] [Abstract][Full Text] [Related]
6. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
Arshad M; Azad A; Chan PYK; Vigneswara V; Feldinger K; Nafi SNM; Laporte-Maguire E; De Santo C; Zuo J; Shaaban AM; Kong A
Br J Cancer; 2024 Apr; ():. PubMed ID: 38600326
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.
Wong AL; Lee SC
Int J Breast Cancer; 2012; 2012():415170. PubMed ID: 22649737
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatics and in vitro study reveals ERα as the potential target gene of Honokiol to enhance trastuzumab sensitivity in HER2+ trastuzumab-resistant breast cancer cells.
Putra IMR; Lestari IA; Fatimah N; Hanif N; Ujiantari NSO; Putri DDP; Hermawan A
Comput Biol Chem; 2024 May; 111():108084. PubMed ID: 38805864
[TBL] [Abstract][Full Text] [Related]
9. "Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper".
Conte P; Ciruelos E; Curigliano G; De Laurentiis M; Del Mastro L; Gennari A; Llombart A; Martìn M; Poggio F; Prat A; Puglisi F; Saura C
Breast; 2024 May; 76():103742. PubMed ID: 38772190
[TBL] [Abstract][Full Text] [Related]
10. Multidrug-resistant breast cancer: current perspectives.
Martin HL; Smith L; Tomlinson DC
Breast Cancer (Dove Med Press); 2014; 6():1-13. PubMed ID: 24648765
[TBL] [Abstract][Full Text] [Related]
11. Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer.
Li R; Sant S; Brown E; Caramia F; Nikolic B; Clarke K; Byrne A; Lara Gonzalez LE; Savas P; Luen SJ; Teo ZL; Virassamy B; Neeson PJ; Darcy PK; Loi S
J Natl Cancer Inst; 2023 Jul; 115(7):805-814. PubMed ID: 37166471
[TBL] [Abstract][Full Text] [Related]
12. ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity.
Mikuličić S; Shamun M; Massenberg A; Franke AL; Freitag K; Döring T; Strunk J; Tenzer S; Lang T; Florin L
Front Immunol; 2024; 15():1335302. PubMed ID: 38370412
[TBL] [Abstract][Full Text] [Related]
13. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y
Front Oncol; 2023; 13():1322078. PubMed ID: 38293701
[TBL] [Abstract][Full Text] [Related]
14. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.
Wei Q; Li P; Yang T; Zhu J; Sun L; Zhang Z; Wang L; Tian X; Chen J; Hu C; Xue J; Ma L; Shimura T; Fang J; Ying J; Guo P; Cheng X
J Hematol Oncol; 2024 Jan; 17(1):1. PubMed ID: 38178200
[TBL] [Abstract][Full Text] [Related]
15. Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer.
Park J; Kang SK; Kwon WS; Jeong I; Kim TS; Yu SY; Cho SW; Chung HC; Rha SY
Sci Rep; 2023 Dec; 13(1):22648. PubMed ID: 38114573
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
Shagisultanova E; Gradishar W; Brown-Glaberman U; Chalasani P; Brenner AJ; Stopeck A; Parris H; Gao D; McSpadden T; Mayordomo J; Diamond JR; Kabos P; Borges VF
Clin Cancer Res; 2023 Dec; 29(24):5021-5030. PubMed ID: 37363965
[TBL] [Abstract][Full Text] [Related]
17. Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF; Bruni S; Mauro FL; Schillaci R
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046648
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs.
Gámez-Chiachio M; Sarrió D; Moreno-Bueno G
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139701
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
